Sanofi

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:37:02 2024-04-26 am EDT			After market 03:59:58 pm
91.23 ^EUR	-0.43%		91.85	+0.68%

12:14pm	Sanofi to present advances at ATS in San Diego	CF
Apr. 25	Health Care Drops Amid Mixed Earnings -- Health Care Roundup	DJ

SANOFI : UBS maintains a Buy rating

December 02, 2021 at 07:27 am EST

UBS analyst Laura Sutcliffe maintains his Buy rating on the stock. The target price is unchanged at EUR 116.

Latest news about Sanofi

Sanofi to present advances at ATS in San Diego	06:14am	CF
Health Care Drops Amid Mixed Earnings -- Health Care Roundup	Apr. 25	DJ
SANOFI : DZ Bank reaffirms its Neutral rating	Apr. 25	ZD
European Equities Close Mostly Lower in Thursday Trading; BHP Bids Nearly $39 Billion to Acquire Anglo American	Apr. 25	MT
CAC40: manages to reduce losses at the end of the session	Apr. 25	CF
Global markets live: Ford, Dow, American Airlines, Comcast, Apple, IBM, Cisco...	Apr. 25
CAC40: losses trimmed, rates remain at their zenith	Apr. 25	CF
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	Apr. 25	MT
CAC40: U.S. growth and inflation hold up, Nasdaq -2%.	Apr. 25	CF
SANOFI : Jefferies reiterates its Buy rating	Apr. 25	ZD
Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday	Apr. 25	MT
Dpa-AFX Overview: COMPANIES from 25.04.2024 - 15:15	Apr. 25	DP
Transcript : Sanofi, Q1 2024 Earnings Call, Apr 25, 2024	Apr. 25
SANOFI : Sanofi’s healthy Q1 performance hailed by markets	Apr. 25
Sanofi Q1 Earnings Fall, Net Sales Climb	Apr. 25	MT
CAC40: down slightly on an avalanche of results	Apr. 25	CF
European Midday Briefing : Mood Cautious Ahead of More U.S Tech, Key Data	Apr. 25	DJ
Sanofi: quarterly EPS down by more than 7% at TCC	Apr. 25	CF
Wall Street: a note of weakness ahead of US GDP figures	Apr. 25	CF
Sanofi Posts Lower Q1 Net Income; Net Sales Up	Apr. 25	MT
Sanofi Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Sanofi Sales, Profit Beat Expectations	Apr. 25	DJ
Sanofi Q1 profit slips on generic competition, forex effects	Apr. 25	RE
EMEA Morning Briefing : Shares Seen Lower; Earnings, U.S. GDP Data in Focus	Apr. 25	DJ
SANOFI : Bernstein remains its Buy rating	Apr. 24	ZD

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).

Sector

Pharmaceuticals

Calendar

2024-04-30 - Annual General Meeting

Related indices

CAC 40 , EURO STOXX 50 , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

SANOFI : Sanofi’s healthy Q1 performance hailed by markets

April 25, 2024 at 07:58 am EDT

Sanofi Sees Trend for Years of Steady Growth: CFO

February 03, 2023 at 03:56 pm EST

More Strategies

Ratings for Sanofi

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

91.62 EUR

Average target price

107.9 EUR

Spread / Average Target

+17.75%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SANOFI	+1.64%	123B
ELI LILLY AND COMPANY	+25.83%	653B
NOVO NORDISK A/S	+27.00%	556B
JOHNSON & JOHNSON	-6.76%	354B
MERCK & CO., INC.	+20.34%	331B
ABBVIE INC.	+3.00%	296B
ASTRAZENECA PLC	+13.09%	233B
NOVARTIS AG	+5.46%	201B
ROCHE HOLDING AG	-9.61%	193B
AMGEN INC.	-6.26%	144B

Other Pharmaceuticals

Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

SANOFI : UBS maintains a Buy rating

Latest news about Sanofi

Chart Sanofi

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Sanofi

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals